Market cap
$1 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.6
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -19.05 | -12.52 | -15.52 | -42.01 | -193.51 |
| Net Profit | -20.41 | -38.48 | -4.20 | -53.52 | -177.54 |
| EPS | -- | -- | -- | -- | -- |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-22 | Dec-21 |
| EBIT-Margin
| -- | -- | -- | -- | -- |
| Net Margin
| -62,939.15 | -62,939.15 | -- | -- | -123,966.03 |
| Return on equity
| -296.21 | 80.90 | -- | -206.87 | -99.87 |
| Return on Capital
| -248.74 | -957.49 | -- | -142.46 | -99.34 |
| Return on Assets
| -162.19 | -331.13 | -137.61 | -109.25 | -82.45 |
| Debt to Equity (x)
| -- | -- | 0.00 | 8.22 | 0.00 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
9 Meters Biopharma (NMTR)
|
--
|
-142.46
|
-99.34
|
-504.44
|
1,190.94
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
9 Meters Biopharma (NMTR)
|
--
|
-206.87
|
-99.87
|
-581.88
|
435.08
|
|
Peer Median
|
-40.33
|
--
|
--
|
--
|
--
|
ROA
-137.61
Lower than Peers by 106.37
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
9 Meters Biopharma (NMTR)
|
-137.61
|
-109.25
|
-82.45
|
-294.87
|
-491.43
|
|
Peer Median
|
-31.24
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
9 Meters Biopharma (NMTR)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-82.60
|
--
|
--
|
--
|
--
|
Net Margin
--
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
9 Meters Biopharma (NMTR)
|
--
|
--
|
-123,966.03
|
-1,912.26
|
--
|
|
Peer Median
|
-91.30
|
--
|
--
|
--
|
--
|
Revenue Growth
--
--
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
9 Meters Biopharma (NMTR)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
54.03
|
--
|
--
|
--
|
--
|
EBIT Growth
-15.52
Lower than Peers by 14.50
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
9 Meters Biopharma (NMTR)
|
-15.52
|
-14.30
|
39.61
|
-138.28
|
-41.46
|
|
Peer Median
|
-1.02
|
--
|
--
|
--
|
--
|
Net Profit Growth
-4.20
Higher than Peers by 3.33
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
9 Meters Biopharma (NMTR)
|
-4.20
|
-23.59
|
43.81
|
-127.00
|
-19.50
|
|
Peer Median
|
-7.53
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
9 Meters Biopharma (NMTR)
|
--
|
8.22
|
0.00
|
0.01
|
-0.34
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
-0.82
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
9 Meters Biopharma (NMTR)
|
-0.82
|
8.20
|
0.00
|
0.00
|
-0.34
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.59
Lower than Peers by 5.22
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
9 Meters Biopharma (NMTR)
|
0.59
|
1.08
|
5.91
|
5.68
|
0.35
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
0.59
Lower than Peers by 5.11
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
9 Meters Biopharma (NMTR)
|
0.59
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-12.28
Lower than Peers by 10.20
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
9 Meters Biopharma (NMTR)
|
-12.28
|
-15.75
|
-779.05
|
-15.05
|
-14.00
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
9 Meters Biopharma (NMTR)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
19.01
|
--
|
--
|
--
|
--
|
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
9 Meters Biopharma (NMTR)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
9 Meters Biopharma (NMTR)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
9 Meters Biopharma (NMTR)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
9 Meters Biopharma (NMTR)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
9 Meters Biopharma (NMTR)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Book Value
1.59
Lower than Peers by 3.74
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
9 Meters Biopharma (NMTR)
|
1.59
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.33
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
9 Meters Biopharma (NMTR)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-0.59
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
9 Meters Biopharma (NMTR)
|
-0.59
|
-0.17
|
1.48
|
1.76
|
0.06
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
1
Lower than Peers by 141
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
9 Meters Biopharma (NMTR)
|
1
|
--
|
--
|
--
|
--
|
|
Peer Median
|
142
|
--
|
--
|
--
|
--
|